Mutlu, H. Et Al. 2014. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. CHEMOTHERAPY , vol.60, no.2 , 107-111.

Mutlu, H., Arslan, D., Gunduz, S., Tural, D., Buyukcelik, A., CIHAN, Y. B., ... ASLAN, T.(2014). The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. CHEMOTHERAPY , vol.60, no.2, 107-111.

Mutlu, HASAN Et Al. "The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy," CHEMOTHERAPY , vol.60, no.2, 107-111, 2014

Mutlu, HASAN Et Al. "The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy." CHEMOTHERAPY , vol.60, no.2, pp.107-111, 2014

Mutlu, H. Et Al. (2014) . "The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy." CHEMOTHERAPY , vol.60, no.2, pp.107-111.

@article{article, author={HASAN MUTLU Et Al. }, title={The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy}, journal={CHEMOTHERAPY}, year=2014, pages={107-111} }